At Pfizer we strive to positively impact the health of people around the world. Our corporate social investment strategy focuses on leveraging the full range of the company's resources — people, skills, expertise and funding — to broaden access to medicines and strengthen health care delivery for underserved people around the world.
Pfizer's Mobilize Against Malaria Initiative is a five-year, three-country initiative that engages and educates treatment providers and patients to improve prompt and effective treatment for malaria in Senegal, Ghana and Kenya. In Kenya, over 1600 staff, working with pregnant women and young children, are trained to advise women on prevention and treatment of malaria in Nyanza and western provinces. Learn more
Pfizer's Mobilize Against Malaria Initiative is a five-year, three-country initiative that engages and educates treatment providers and patients to improve prompt and effective treatment for malaria in Senegal, Ghana and Kenya. In the Ashanti Region of Ghana, over 1200 Licensed Chemical Sellers (LCS) trained to correctly dose and administer artemisinin-based combination therapy (ACT), and to recognize and refer complicated malaria cases to the nearest health facility. Learn more
Pfizer's Mobilize Against Malaria Initiative is a five-year, three-country initiative that engages and educates treatment providers and patients to improve prompt and effective treatment for malaria in Senegal, Ghana and Kenya. In Tambacounda, Senegal, community health workers were trained in malaria diagnosis and treatment at 24 health huts. All health huts were also equipped with furniture, basic medical and surgical instruments, health management tools, artemisinin-based combination therapies (ACT) and notice boards. Learn more
In 2006, after receiving Pfizer-donated Zithromax® for six years and implementing the full SAFE strategy in endemic districts, Morocco achieved its ultimate intervention goals and is working toward WHO certification of elimination of blinding trachoma. Learn more
The Amhara Regional Health Bureau, with support from the International Trachoma Initiative, the Carter Center and Lions Clubs, has distributed Zithromax® to more than 14.7 million people since 2008. More than 4 million doses were distributed in other parts of Ethiopia. Learn more
Pfizer's partners are working in the Rift Valley region, bordering Southern Sudan and Uganda, and targeting a trachoma elimination date of 2015. Learn more
Since 2007, more than 2.9 million doses of Zithromax® have been distributed in 11 districts as part of the SAFE strategy recommended by the World Health Organization. The SAFE strategy uses Surgery, Antibiotics (using dontated Zithromax®), Facial cleanliness, and Environmental improvement to combat and prevent the disease. Learn more
The International Trachoma Intiative works with WHO to get Pfizer-donated Zithromax® into Senegal and is advocating for the implementation of the SAFE strategy. The SAFE strategy uses Surgery, Antibiotics (using dontated Zithromax®), Facial cleanliness, and Environmental improvement to combat and prevent the disease. Learn more
The International Trachoma Initiative Technical Expert Committee has approved the Zithromax® donation in Zambia, which may have more than 72 endemic districts. The country is now undertaking prevalence studies and supply chain improvements to begin trachoma elimination work. Learn more
Vietnam no longer requires mass dosing of Zithromax®. However, international partners are working to clear a backlog of trichiasis surgeries before seeking certification of trachoma elimination. Trichiasis surgery reverses an advanced stage of trachoma in which the eyelashes turn inward and scrap the cornea, causing blindness. Learn more
In partnership with the U.S. Agency for International Development (USAID), and RTI Internaional, the International Trachoma Initiative has been working with the government of Nepal since 2002. Nepal has made solid progress toward trachoma elimination and is now working to scale-up the SAFE strategy. Nepal plans to reach a target elimination date of 2015. Learn more
Through Global Health Partnerships (GHP), Pfizer is investing $47 million to promising cancer- and tobacco-control organizations working towards bold advancements in the fight against cancer. Through GHP, the Ralph Lauren Center for Cancer Care and Prevention in New York City has expanded its patient navigation model to five additional underserved locations across the US and, to date, they have navigated more than 4,500 patients through their cancer care and treatments. Learn more
Through Global Health Partnerships (GHP), Pfizer is investing $47 million to promising cancer- and tobacco-control organizations working towards bold advancements in the fight against cancer. The Mexico Council Against Tobacco has embarked on a sweeping tobacco-control initiative helping raise awareness among policy-makers and opinion leaders as to the importance of smoke-free environments. In May 2009, the General Tobacco Control Law was enacted at the national level. Learn more
Through Global Health Partnerships (GHP), Pfizer is investing $47 million to promising cancer- and tobacco-control organizations working to accelerate progress in the fight against cancer. The Alliance for the Control of Tobacco Use mobilizes the Brazilian community and media through public opinion polls and public demonstrations. Their efforts contributed to the April 2009 approval of a 100 percent smoke-free law in Sáo Paulo State; and in August 2009, Rio de Janeiro State approved its smoke-free law. Learn more
Through Global Health Partnerships (GHP), Pfizer is investing $47 million to promising cancer- and tobacco-control organizations working to accelerate progress in the fight against cancer. In Turkey, Pfizer is supporting The New Hope in Health Foundation (SUVAK) to improve capacity to maintain high quality cancer registry data and to use this information to rally the nation's advocacy groups and the Turkish Thoracic Society that aims to build infrastructure that trains healthcare providers, establishes smoking cessation support centers and educates the general smoking population on smoking cessation options. Learn more
Through Global Health Partnerships (GHP), Pfizer is investing $47 million over four years in the growth of 31 promising cancer- and tobacco-control organizations united by the shared mission of accelerating the pace of progress in the fight against cancer. In China, Pfizer is combating both cancer and tobacco by supporting the Cancer Foundation of China, the Shanghai Municipal Center for Disease Control and Prevention (SCDC) and the China Association on Tobacco Control (CATC). The Cancer Foundation of China is building cancer-control capacity and improving cancer-control education for healthcare professionals with a special emphasis on rural areas. The SCDC is improving screening, diagnosis, and referral rates in order to reduce late-stage diagnoses in breast, colorectal, and other common cancers. CATC is converting 60 hospitals to smoke-free status and educating healthcare providers, patients, and family members about the dangers of tobacco. CATC's success has led to the Chinese government's announcement of "Decisions on Smoking Ban Throughout Medical and Healthcare Sector of the Country Starting from 2011" to ban smoking in medical institutions by the end of 2011. Learn more
Across Asia, Pfizer is addressing both tobacco and cancer control through Global Health Partnerships. The Health Partnerships Institute of Japan is identifying regional disparities in cancer and tobacco control and instituting training and advocacy to address them. Akebono-kai has launched public education and screening campaigns across Tokyo to double the screening rate among women over 40. The Japan Medical Dental Association initiated the Japan Smoking Cessation Training Outreach Project (J-STOP) to coordinate efforts with other associations to train at least 1,000 healthcare providers on best practices in smoking cessation. The American Cancer Society Asia program is providing technical assistance for 11 promising grassroots initiatives in Malaysia, the Philippines, Singapore, Taiwan, and Thailand to improve access to and utilization of cancer control services, and to build capacity for early detection and patient support. Learn more
Through Global Health Partnerships (GHP), Pfizer is investing $47 million to promising cancer- and tobacco-control organizations working towards bold advancements in the fight against cancer. In Asia, through improved capacity to deliver early detection programs and advocacy strategies, the American Cancer Society is supporting 14 cancer organizations from Thailand, Malaysia, Taiwan, the Philippines and Singapore in providing screenings for more than 7,000 individuals and educating 52,000+ individuals about cancer early detection. Learn more
The Pfizer Foundation funded efforts in communities disproportionately affected by HIV/AIDS in 10 states in the U.S. with high incidence of HIV/AIDS. The St. Hope Foundation in Houston developed new tools to help men and women develop the skills they need to use condoms consistently and focused on high-risk African-American and Latino populations. The program served 270 high-risk individuals, reducing their risk behavior and linking 100% of those in need with additional care. Learn more
With ConnectHIV support, the American Cancer Society developed "Positive Choices," a Comprehensive Risk Counseling and Services (CRCS) program, to improve the quality of life, reduce disease progression, improve disease outcomes, and limit further HIV exposure and transmission among their community's most vulnerable members in North Carolina. Learn more
In partnership with Makerere University, the Academic Alliance and Accordia Global Health Foundation, the Ugandan Ministry of Health and Mulago Hospital and Pfizer, the Infectious Diseases Institute was established in 2004 as a Center of Excellence for prevention, treatment, training and research in Uganda that strengthens regional capacity in HIV/AIDS, malaria, tuberculosis and other infectious diseases. Learn more
Over five years (2004 – 2008), Pfizer Helpful Answers has helped over 5.1 million patients in the U.S. receive over 51 million Pfizer prescriptions, the equivalent of $4.8 billion worth of free medicines and savings. Learn more
Since 2003, Pfizer's Diflucan® Partnership Program has donated over 760,000 free Diflucan® (Fluconazole) treatments for two AIDS-related fungal opportunistic infections, namely, cryptococcal meningitis and esophageal candidiasis to Governments and non-governmental organizations in this region. Learn more
Since 2003, the Diflucan® Partnership Program has donated over 1 million free Diflucan® (Fluconazole) treatments for two AIDS-related fungal opportunistic infections, namely, cryptococcal meningitis and esophageal candidiasis to Governments and non-governmental organizations in this region. Learn more
In July 2010, Pfizer provided $30,000 in financial assistance to the Mexican Red Cross in response to "Hurricane Alex."
In 2010 Pfizer provided over $5 million in cash and product contribution to assist the people of Haiti affected by the January 2010 earthquake. Pfizer also provided $100,000 to the Chilean Red Cross in response to the April 2010 earthquake in Chile. In January 2011 Pfizer provided $30,000 to support flooding victims in Colombia and Venezuela.
Pfizer provided $700,000 in financial assistance to provide relief after the April 2010 earthquake in the Qinghai province.
In August 2010 Pfizer provided $85,000 in financial assistance to UNICEF and other organizations for flood relief.
Pfizer's GHF program, a skills-based volunteer program, has placed Pfizer colleagues with international development organizations to strengthen health systems. Learn more
Pfizer's GHF program, a skills-based volunteer program, has placed Pfizer colleagues with international development organizations to strengthen health systems. Learn more
Pfizer's GHF program, a skills-based volunteer program, has placed Pfizer colleagues with international development organizations to strengthen health systems. Learn more
Pfizer's GHF program, a skills-based volunteer program, has placed Pfizer colleagues with international development organizations to strengthen health systems. Learn more
Pfizer's GHF program, a skills-based volunteer program, has placed Pfizer colleagues with international development organizations to strengthen health systems. Learn more
Pfizer's GHF program, a skills-based volunteer program, has placed Pfizer colleagues with international development organizations to strengthen health systems. Learn more
Pfizer's GHF program, a skills-based volunteer program, has placed Pfizer colleagues with international development organizations to strengthen health systems. Learn more
Pfizer's GHF program, a skills-based volunteer program, has placed Pfizer colleagues with international development organizations to strengthen health systems. Learn more
Pfizer's GHF program, a skills-based volunteer program, has placed Pfizer colleagues with international development organizations to strengthen health systems. Learn more
Pfizer's GHF program, a skills-based volunteer program, has placed Pfizer colleagues with international development organizations to strengthen health systems. Learn more
Pfizer's GHF program, a skills-based volunteer program, has placed Pfizer colleagues with international development organizations to strengthen health systems. Learn more
Pfizer's GHF program, a skills-based volunteer program, has placed Pfizer colleagues with international development organizations to strengthen health systems. Learn more
Pfizer's GHF program, a skills-based volunteer program, has placed Pfizer colleagues with international development organizations to strengthen health systems. Learn more
Pfizer's GHF program, a skills-based volunteer program, has placed Pfizer colleagues with international development organizations to strengthen health systems. Learn more
Pfizer's GHF program, a skills-based volunteer program, has placed Pfizer colleagues with international development organizations to strengthen health systems. Learn more
Pfizer's GHF program, a skills-based volunteer program, has placed Pfizer colleagues with international development organizations to strengthen health systems. Learn more
Pfizer's GHF program, a skills-based volunteer program, has placed Pfizer colleagues with international development organizations to strengthen health systems. Learn more
Pfizer's GHF program, a skills-based volunteer program, has placed Pfizer colleagues with international development organizations to strengthen health systems. Learn more
Pfizer's GHF program, a skills-based volunteer program, has placed Pfizer colleagues with international development organizations to strengthen health systems. Learn more
Pfizer's GHF program, a skills-based volunteer program, has placed Pfizer colleagues with international development organizations to strengthen health systems. Learn more
Since 2002, the Diflucan® Partnership Program has donated over 17 million free Diflucan® (Fluconazole) treatments for two AIDS-related fungal opportunistic infections, namely, cryptococcal meningitis and esophageal candidiasis to Governments and non-governmental organizations in this region. Learn more
Since 2002, Pfizer's Diflucan® Partnership Program has distributed over 8.3 million free Diflucan® (Fluconazole) treatments to more than 300 health facilities in Uganda, for the treatment of patients presenting with two opportunistic infections commonly associated with HIV and AIDS, namely, cryptococcal meningitis and esophageal candidiasis. Learn more
Since 2003 Pfizer's Diflucan® Partnership Program has distributed over 4.5 million free Diflucan® (Fluconazole) treatments to more than 190 health facilities in Kenya, for the treatment of patients presenting with two opportunistic infections commonly associated with HIV and AIDS, namely, cryptococcal meningitis and esophageal candidiasis. Learn more
Pfizer's Diflucan® Partnership Program has donated over 51.4 million free Diflucan® (Fluconazole) treatments in this region since 2001 to governments and non-governmental organizations for two AIDS-related fungal opportunistic infections, namely, cryptococcal meningitis and esophageal candidiasis. Learn more
December 1, 2010 marked 10 years of successful implementation of the Diflucan® program in South Africa; they were the first country to lauch the program in December 2000 and the largest partner to date. Learn more
Pfizer's Diflucan® Partnership Program has donated over 1.3 million free Diflucan® (Fluconazole) treatments to governments and non-governmental organizations for two AIDS-related fungal opportunistic infections, namely, cryptococcal meningitis and esophageal candidiasis in this region. Learn more
Pfizer's programs in the United States of America include our patient assistance program, skills-based employee investments, addressing chronic non-communicable diseases, HIV/AIDS prevention programs and disaster relief.
Pfizer's programs in Mexico focus on addressing chronic non-communicable diseases, skills-based employee investments, and disaster relief.
Pfizer's programs in Latin Ameria focus on the prevention and treatment of HIV-related infections, skills-based employee investments, addressing chronic non-communicable diseases and skills-based employee investments.
Pfizer's programs in Europe focus on addressing chronic non-communicable diseases and skills-based employee investments.
Pfizer's programs in Asia focus on the prevention and treatment of HIV-related infections, addressing chronic non-communicable diseases, skills-based employee investments working towards the elimination of blinding trachoma and disaster relief.
Pfizer's programs in Africa focus on the prevention and treatment of HIV-related infections, working towards the elimination of blinding trachoma partnering for care and prevention of infectious diseases, mobilizing against malaria and skills-based employee investments.
Following the April and May 2011 storms in the Southeastern and Midwestern parts of the United States, Pfizer provided $150,000 in financial assistance to six nonprofit organizations.
Following the February 2011 earthquake and tsunami, Pfizer donated $7.57 million to disaster relief efforts, including $3.26 million in medicines distributed to affected areas.
